All articles tagged with #trumprx
TrumpRx.gov, launched to curb prescription costs, has offered discounts on only 54 drugs—many with cheaper generics or other savings options—and remains far from an insurance-friendly tool, with limited awareness; experts say its real impact hinges on scale, broader drug coverage, price transparency, and potential congressional action to codify MFN-style deals into law.
One month after its launch, TrumpRx has only a small catalog of drugs (44 listed) despite lofty promises of broad discounts, with many items already available as generics and no clear usage data released. Private deals with drugmakers remain in flux, limiting impact on prices, while administration officials trumpet progress amid bipartisan scrutiny and questions about affordability gains for most patients.
The White House launched TrumpRx (trumprx.gov) to help uninsured Americans find discounted prices for high-cost, brand-name drugs. It doesn’t sell drugs directly; users browse discounted medicines and either receive coupons at pharmacies or are redirected to manufacturers’ sites. Discounts come from voluntary 'most favored nation' deals with 16 major drugmakers, but full terms are not public. Economists say the savings are likely modest and mainly increase price transparency; the platform could help those not covered by insurance, especially for lifestyle drugs like fertility or weight-loss treatments. Democrats criticize it as a vanity project and raise concerns about potential conflicts with BlinkRx and Trump family involvement; long-term impact remains uncertain.
Trump announced TrumpRx, a new online portal that lists discounted prices for 43 commonly used drugs and directs consumers to manufacturers’ sites to complete purchases. The site does not sell meds or accept insurance; discounts apply only to cash-paying patients, with no impact on insurance deductibles. The White House says the portal offers immediate relief and plans to expand with more drugmakers, including notable discounts such as Wegovy as low as $149/month. It’s intended as a price-checking tool rather than a storefront.
The Trump administration unveiled TrumpRx.gov, a government site that lets users look up prescription drugs and then navigate to buy them elsewhere; it does not sell meds itself. It lists 43 drugs with prices from $3 to over $5,500 and warns that using insurance may yield lower co-pays, highlighting continued price-comparison challenges in the prescription market.
President Trump unveiled TrumpRx, a direct-to-consumer site offering discounts on about 40 branded medicines from five major drugmakers with GoodRx backing; experts say savings may be muted for many since insurance plans and deductibles often yield lower costs, and pricing details remain unclear. The administration touts it as transformative, but critics warn it could curb competition and that broader Medicare drug-price negotiations would be more effective. A potential Express Scripts agreement could expand coverage if the regulatory environment allows, signaling that Congress may need to act to count purchases toward deductibles.
The Trump administration unveiled TrumpRx, a White House-backed website intended to help patients buy prescription drugs directly at discounted rates, as part of a push to address rising healthcare and living costs.
The White House announced TrumpRx, a direct-to-consumer hub that directs cash-paying patients to discounts offered by drugmakers on their own sites, as part of efforts to lower U.S. prescription costs. The site does not sell drugs itself and may not benefit insured patients who rely on coverage, but could help uninsured or underinsured access drugs not widely covered, such as obesity medications; participating makers include Lilly and Novo Nordisk, with prices advertised (e.g., Ozempic and Wegovy at about $350/month) amid broader debated savings, since actual prices often depend on rebates and payer contracts. The overall impact on out-of-pocket costs remains uncertain.
President Trump is rolling out TrumpRx.gov, a government site intended to help Americans buy discounted prescription medicines as part of his broader bid to extract price concessions from drugmakers; experts say the plan could offer some savings but is unlikely to dramatically lower costs or reshape the pharmaceutical market.
AbbVie and the Trump administration announced a three-year agreement to boost U.S. access and affordability: AbbVie will offer low Medicaid prices, expand direct-to-patient access via the TrumpRx program for medicines including ALPHAGAN, COMBIGAN, HUMIRA and SYNTHROID, and commit $100 billion in U.S.-based R&D and manufacturing investments over the next decade, in exchange for tariff relief and exemption from future price mandates; the deal aims to address all four of the President's drug pricing priorities, with terms kept confidential.
Nine pharmaceutical companies have committed to President Trump's drug pricing policies, including lowering U.S. prices for some drugs and participating in the upcoming TrumpRx platform, as part of a broader effort to align U.S. drug prices with those in other developed countries and promote domestic manufacturing. The deals involve offering drugs at most favored nation prices, investing in domestic production, and donating ingredients to the national stockpile, though some drugs are already available as generics.
President Trump announced a deal with Eli Lilly and Novo Nordisk to significantly reduce the prices of popular weight loss drugs for eligible Medicare and Medicaid patients, with plans to launch the TrumpRx program offering these medications at lower costs starting in January, aiming to improve health outcomes and reduce obesity-related risks.
The White House announced a deal to significantly reduce the cost of IVF drugs on the TrumpRx platform, with over 70% discounts for drugs like Gonal-F, Ovidrel, and Cetrotide, and plans to encourage employers to offer more IVF coverage, although it stops short of providing universal free IVF.
The article criticizes the launch of TrumpRx, a new government healthcare website associated with Donald Trump, highlighting its narcissistic branding, disturbing AI-generated images, and questionable claims about lowering drug prices, while also noting potential conflicts of interest involving Trump's family.
AstraZeneca has agreed with the Trump administration to lower drug prices through a deal that includes most-favored-nation pricing for Medicaid and discounts for direct consumer sales, along with expanding manufacturing in the U.S. and receiving tariff exemptions, as part of broader efforts to align U.S. drug prices with those in other developed countries.